On June 24, 2026 Biosidus, one of Latin America’s pioneering biotechnology companies, reported the signing of a licensing and supply agreement with Mubadala Bio, the life sciences platform of Mubadala Investment Company, to introduce a portfolio of biologic therapies in the United Arab Emirates through DiabTec, Mubadala Bio’s biologics platform.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The agreement was signed during BIO International Convention 2026 and was witnessed by Dr. Noura Al Ghaithi, Undersecretary of the Department of Health – Abu Dhabi.
The collaboration includes biologic therapies across endocrinology, nephrology and oncology, including epoetin alfa, filgrastim, interferon beta and somatropin.
Hamad Almarzooqi, Group Deputy CEO of Mubadala Bio, said:
"Strategic partnerships enable us to localize medicines that are important to healthcare providers and their patients. Through our collaboration with Biosidus, we are increasing access to biologic therapies in the UAE while advancing our commitment to local pharmaceutical manufacturing."
Mariano de Elizalde, CEO of Biosidus, said:
"We are honored to partner with Mubadala Bio in support of its mission to strengthen healthcare resilience and expand access to advanced biologic therapies in the UAE. This agreement represents an important milestone in Biosidus’ international growth strategy and reflects our shared commitment to innovation, quality and patient access."
The agreement adds a key international partner to support our continued growth in strategic Regions and further strengthens Biosidus’ position as a biotechnology partner of choice for healthcare systems and life sciences organizations across both emerging and developed markets.
(Press release, Biosidus, JUN 24, 2026, View Source [SID1234668940])